Effect of time to titration to maximum dose of statins on cardiovascular outcomes

A retrospective analysis in high-risk patients

Amy S. Friend, Masoor Kamalesh, Ellen Schellhase, George J. Eckert, Tamara S. Evans

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Recent trials have shown that high-dose HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular events in high-risk subjects within weeks of initiating therapy. We investigated the effect of time to titration to maximum dose of statin therapy on cardiovascular events. Methods: From a list of all patients actively taking simvastatin 80 mg/day as of April 2003 at our hospital, two clinical pharmacists reviewed 213 electronic medical records including pharmacy records from November 1992 to April 2003. Data on cardiovascular risk factors, laboratory results, titration schedules, and outcomes were extracted from the electronic database. Titration period time frames were compared between patient groups using a Student t-test and multiple-variable logistic regression to account for other risk factors. Results: Titration schedules and time frames to attain a regimen of simvastatin 80mg/day were available for 154 (73%) subjects. Titrations ranged from 1 to 8 and averaged 2.3 ? 1.3 titrations per patient (median titrations = 2) over 1 month to 8.4 years. On follow-up, 47 patients experienced 80 cardiovascular-related outcomes. The average time to titration to maximum dose of statin therapy was longer for patients who experienced a cardiac event than for those who did not (3.5 ? 2.2 vs 2.1 ? 1.8 years; p = 0.0004). After accounting for other risk factors, the titration period was still significantly related to the presence of a cardiac event (p = 0.0060, odds ratio per month increase in the titration period 1.3, 95% CI 1.08, 1.58). Conclusions: Despite potential limitations, the results of our study show that an excessive delay in titrating statin therapy to the optimal dose may lead to an increased risk of atherosclerosis-related events in high-risk patients.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalAmerican Journal of Cardiovascular Drugs
Volume9
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Simvastatin
Appointments and Schedules
Therapeutics
Electronic Health Records
Pharmacists
Atherosclerosis
Logistic Models
Odds Ratio
Databases
Students

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of time to titration to maximum dose of statins on cardiovascular outcomes : A retrospective analysis in high-risk patients. / Friend, Amy S.; Kamalesh, Masoor; Schellhase, Ellen; Eckert, George J.; Evans, Tamara S.

In: American Journal of Cardiovascular Drugs, Vol. 9, No. 2, 2009, p. 103-107.

Research output: Contribution to journalArticle

@article{e2e34213c42a4c7cb73f566be17ffc5d,
title = "Effect of time to titration to maximum dose of statins on cardiovascular outcomes: A retrospective analysis in high-risk patients",
abstract = "Background: Recent trials have shown that high-dose HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular events in high-risk subjects within weeks of initiating therapy. We investigated the effect of time to titration to maximum dose of statin therapy on cardiovascular events. Methods: From a list of all patients actively taking simvastatin 80 mg/day as of April 2003 at our hospital, two clinical pharmacists reviewed 213 electronic medical records including pharmacy records from November 1992 to April 2003. Data on cardiovascular risk factors, laboratory results, titration schedules, and outcomes were extracted from the electronic database. Titration period time frames were compared between patient groups using a Student t-test and multiple-variable logistic regression to account for other risk factors. Results: Titration schedules and time frames to attain a regimen of simvastatin 80mg/day were available for 154 (73{\%}) subjects. Titrations ranged from 1 to 8 and averaged 2.3 ? 1.3 titrations per patient (median titrations = 2) over 1 month to 8.4 years. On follow-up, 47 patients experienced 80 cardiovascular-related outcomes. The average time to titration to maximum dose of statin therapy was longer for patients who experienced a cardiac event than for those who did not (3.5 ? 2.2 vs 2.1 ? 1.8 years; p = 0.0004). After accounting for other risk factors, the titration period was still significantly related to the presence of a cardiac event (p = 0.0060, odds ratio per month increase in the titration period 1.3, 95{\%} CI 1.08, 1.58). Conclusions: Despite potential limitations, the results of our study show that an excessive delay in titrating statin therapy to the optimal dose may lead to an increased risk of atherosclerosis-related events in high-risk patients.",
author = "Friend, {Amy S.} and Masoor Kamalesh and Ellen Schellhase and Eckert, {George J.} and Evans, {Tamara S.}",
year = "2009",
doi = "10.2165/00129784-200909020-00004",
language = "English",
volume = "9",
pages = "103--107",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of time to titration to maximum dose of statins on cardiovascular outcomes

T2 - A retrospective analysis in high-risk patients

AU - Friend, Amy S.

AU - Kamalesh, Masoor

AU - Schellhase, Ellen

AU - Eckert, George J.

AU - Evans, Tamara S.

PY - 2009

Y1 - 2009

N2 - Background: Recent trials have shown that high-dose HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular events in high-risk subjects within weeks of initiating therapy. We investigated the effect of time to titration to maximum dose of statin therapy on cardiovascular events. Methods: From a list of all patients actively taking simvastatin 80 mg/day as of April 2003 at our hospital, two clinical pharmacists reviewed 213 electronic medical records including pharmacy records from November 1992 to April 2003. Data on cardiovascular risk factors, laboratory results, titration schedules, and outcomes were extracted from the electronic database. Titration period time frames were compared between patient groups using a Student t-test and multiple-variable logistic regression to account for other risk factors. Results: Titration schedules and time frames to attain a regimen of simvastatin 80mg/day were available for 154 (73%) subjects. Titrations ranged from 1 to 8 and averaged 2.3 ? 1.3 titrations per patient (median titrations = 2) over 1 month to 8.4 years. On follow-up, 47 patients experienced 80 cardiovascular-related outcomes. The average time to titration to maximum dose of statin therapy was longer for patients who experienced a cardiac event than for those who did not (3.5 ? 2.2 vs 2.1 ? 1.8 years; p = 0.0004). After accounting for other risk factors, the titration period was still significantly related to the presence of a cardiac event (p = 0.0060, odds ratio per month increase in the titration period 1.3, 95% CI 1.08, 1.58). Conclusions: Despite potential limitations, the results of our study show that an excessive delay in titrating statin therapy to the optimal dose may lead to an increased risk of atherosclerosis-related events in high-risk patients.

AB - Background: Recent trials have shown that high-dose HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular events in high-risk subjects within weeks of initiating therapy. We investigated the effect of time to titration to maximum dose of statin therapy on cardiovascular events. Methods: From a list of all patients actively taking simvastatin 80 mg/day as of April 2003 at our hospital, two clinical pharmacists reviewed 213 electronic medical records including pharmacy records from November 1992 to April 2003. Data on cardiovascular risk factors, laboratory results, titration schedules, and outcomes were extracted from the electronic database. Titration period time frames were compared between patient groups using a Student t-test and multiple-variable logistic regression to account for other risk factors. Results: Titration schedules and time frames to attain a regimen of simvastatin 80mg/day were available for 154 (73%) subjects. Titrations ranged from 1 to 8 and averaged 2.3 ? 1.3 titrations per patient (median titrations = 2) over 1 month to 8.4 years. On follow-up, 47 patients experienced 80 cardiovascular-related outcomes. The average time to titration to maximum dose of statin therapy was longer for patients who experienced a cardiac event than for those who did not (3.5 ? 2.2 vs 2.1 ? 1.8 years; p = 0.0004). After accounting for other risk factors, the titration period was still significantly related to the presence of a cardiac event (p = 0.0060, odds ratio per month increase in the titration period 1.3, 95% CI 1.08, 1.58). Conclusions: Despite potential limitations, the results of our study show that an excessive delay in titrating statin therapy to the optimal dose may lead to an increased risk of atherosclerosis-related events in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=63849275730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849275730&partnerID=8YFLogxK

U2 - 10.2165/00129784-200909020-00004

DO - 10.2165/00129784-200909020-00004

M3 - Article

VL - 9

SP - 103

EP - 107

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 2

ER -